Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16118741 | 1.00 | TSHR (0.48) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL16118742 | 1.00 | TSHR (0.48) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL16875369 | 0.87 | TSHR (0.47) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL16886406 | 0.87 | TSHR (0.47) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL16875325 | 0.87 | TSHR (0.47) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL6758987 | 0.85 | ALDH1A1 (0.50) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL6876401 | 0.85 | ALDH1A1 (0.50) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL1907855 | 0.85 | ALDH1A1 (0.50) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL850188 | 0.85 | FABP7 (0.50) | TSHRFABP7FABP5ALDH1A1HPGD | |
| SCHEMBL6666657 | 0.84 | FABP7 (0.58) | TSHRFABP7FABP5ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| CN-111196804-B | TGF-beta R1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| CN-111196804-A | TGF- β R1 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| CN-105143212-B | Tripeptide epoxy ketone protease inhibitors | 欧尼斯治疗公司 | 2018-02-23 | — | — | CN | disclosed |
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| CN-105143212-A | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS INC | 2015-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | TSHR 4110/4885FABP7 558/4885FABP5 2480/4885 |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | TSHR 4110/4885FABP7 558/4885FABP5 2480/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | TSHR 4110/4885FABP7 558/4885FABP5 2480/4885 |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | TSHR 4110/4885FABP7 558/4885FABP5 2480/4885 |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | TSHR 1369/4885FABP7 4248/4885FABP5 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.